Analgesic Ear Drops for Children With Acute Otitis Media

Pain Clinical Trial

— OPTIMA  

Official title:

Effectiveness of Analgesic Ear Drops as add-on Treatment to Oral Analgesics in Children With Acute Otitis Media: a Pragmatic Randomised Controlled Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05651633
• Other study ID #: 80-87200-98-1017
• Secondary ID: NL95001006001191
• Status: Terminated
• Phase: Phase 3
• Start date: October 6, 2021
• Est. completion date: January 10, 2024

Study information

• Verified date: May 2024
• Source: UMC Utrecht
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial aims to investigate whether analgesic ear drops added to usual care provide superior ear pain relief over usual care alone in children presenting to primary care with AOM. Children will be randomly allocated (ratio 1:1) to either 1) lidocaine hydrochloride 5mg/g ear drops (Otalgan) 1-2 drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics) or 2) usual care. Parents will complete a symptom diary for 4 weeks as well as generic and disease-specific quality of life questionnaires at baseline and 4 weeks. The primary outcome is the parent-reported ear pain score (0-10) over the first 3 days.

NOTE:

At the time of publication of the study protocol paper, the investigators were unable to make any amendments to the trial registration record in the Netherlands Trial Register (NTR) (NL9500; date of registration: 28 May 2021). The addition of a data sharing plan was required to adhere to the International Committee of Medical Journal Editors (ICMJE) guidelines. The investigators therefore re-registered the trial in ClinicalTrials.gov. This second registration is for modification purposes only and the NTR record (NL9500) should be regarded as the primary trial registration.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 29
• Est. completion date: January 10, 2024
• Est. primary completion date: December 16, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 6 Years

Eligibility

Inclusion Criteria:

• Age 1 to 6 years

• Parent-reported ear pain in 24 hours prior to enrolment

• GP-diagnosis of (uni- or bilateral) AOM

Exclusion Criteria:

• with (suspected) tympanic membrane perforation or ventilation tubes

• with ear wax obscuring visualisation of the tympanic membrane

• who are systemically very unwell or require hospital admission (e.g. child has signs and symptoms of serious illness and/or complications such as mastoiditis/meningitis)

• who are at high risk of serious complications including children with known immunodeficiency other than partial IgA or IgG2 deficiencies, craniofacial malformation including cleft palate, Down syndrome and previous ear surgery (with the exception of ventilation tubes in the past)

• who have a known allergy or sensitivity to study medication or similar substances (e.g. other amide-type anaesthetics: bupivacaine, mepivacaine, prilocaine, etc)

• who have taken part in any research involving medicines within the last 90 days, or any other AOM-related research within the last 30 days

• who suffer from chronic recurrent pain of another origin than the ear

• who have participated in this trial during prior AOM episode

Related Conditions & MeSH terms

• Acute Otitis Media
• Otitis
• Otitis Media
• Pain

Intervention

Drug:
• lidocaine hydrochloride 5mg/g
1-2 drops up to six times daily for a maximum of 7 days

Locations

Country	Name	City	State
Netherlands	University Medical Center Utrecht	Utrecht

Sponsors (1)

Lead Sponsor	Collaborator
UMC Utrecht

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The parent-reported ear pain score over the first three days	Parents will record their child's ear pain scores during the first three consecutive days using a 0-10 validated numerical rating scale. Higher scores indicate greater severity.	3 days
Secondary	proportion of children consuming antibiotics		in the first 7 days
Secondary	proportion of children with oral analgesic use		in the first 7 days
Secondary	overall symptom burden (crying/distress, disturbed sleep, interference with normal activity, appetite, fever and hearing problems) using a 0-6 Likert scale	higher scores indicate greater severity	in the first 7 days
Secondary	number of days with ear pain		during follow up (4 weeks)
Secondary	number of GP reconsultations with/without subsequent antibiotic prescribing		during follow-up (4 weeks)
Secondary	number of participants with adverse events		during follow-up (4 weeks)
Secondary	number of participants with complications of AOM		during follow-up (4 weeks)
Secondary	costs	Mean costs per patient will be compared across the randomisation groups	during follow-up (4 weeks)
Secondary	generic quality of life of the child assessed using the 47-item short-form of the Infant Toddler Quality of Life Questionnaire (ITQOL-SF47)	The questionnaire consists of 47 items in the following areas: overall health, physical abilities, growth and development, pain, temperament and moods, behavior, general health, parental emotional impact, parental time impact, and family cohesion. Scale for each area: from 0 (worst health) to 100 (best health)	at baseline and at 4 weeks
Secondary	disease-specific quality of life of the child assessed using the Otitis media-6 (OM-6) questionnaire	The 6 questions measure Physical Suffering, Hearing Loss, Speech Impairment, Emotional Distress, Activity Limitations, and Caregiver Concerns. Responses for each item were scored from 1 to 7 (1=Not present/no problem; 2=Hardly a problem at all; 3=Somewhat of a problem; 4=Moderate problem; 5=Quite a bit of a problem; 6=Very much of a problem; 7=Extreme problem). A mean score of all six items comprises the OM Total Score. Higher mean scores of all six items indicate greater severity and impact of OM on the child's QOL.	at baseline and at 4 weeks
Secondary	incremental cost-effectiveness ratios; calculated by dividing the estimated differences in costs between groups by the differences in effects observed	i.e. the additional cost per additional 1 point reduction in mean ear pain score over the first three days for the analgesic ear drops group versus the usual care group	during follow-up (4 weeks)